197 related articles for article (PubMed ID: 36709172)
21. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
22. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
24. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
26. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic and genetic features of the starry-sky pattern in double-expressor diffuse large B-cell lymphoma.
Sung HJ; Kim D; Yoon DH; Cho H; Huh J; Suh CW; Go H
Hum Pathol; 2023 Sep; 139():106-116. PubMed ID: 37517597
[TBL] [Abstract][Full Text] [Related]
28. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
29. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
30. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
31. [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].
Zhan J; Yang SJ; Zhang W; Zhou DB; Zhang Y; Wang W; Wei C
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):41-47. PubMed ID: 35231992
[No Abstract] [Full Text] [Related]
32. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
33. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
Zhou M; Wang J; Ouyang J; Xu JY; Chen B; Zhang QG; Zhou RF; Yang YG; Shao XY; Xu Y; Chen YM; Fan XS; Wu HY
Tumour Biol; 2014 Jul; 35(7):6757-62. PubMed ID: 24719189
[TBL] [Abstract][Full Text] [Related]
34. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
[TBL] [Abstract][Full Text] [Related]
35. Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Bonnet A; Bossard C; Gabellier L; Rohmer J; Laghmari O; Parrens M; Sarkozy C; Dulery R; Roland V; Llamas-Gutierrez F; Oberic L; Fornecker LM; Bounaix L; Villemagne B; Szablewski V; Choquet S; Bouabdallah K; Traverse-Glehen A; Mohty M; Sanhes L; Houot R; Gastinne T; Leux C; Le Gouill S
Cancer Med; 2022 Oct; 11(19):3602-3611. PubMed ID: 35538643
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
37. [Rituximab-Based Regimens for Treatment of Primary Gastric Diffuse Large B-Cell Lymphoma].
Qu S; Liao LS; Zheng ZH; Xie Y; Chen WM; Chen BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):760-764. PubMed ID: 35680802
[TBL] [Abstract][Full Text] [Related]
38. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
39. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Jovanović MP; Jaković L; Bogdanović A; Marković O; Martinović VC; Mihaljević B
Vojnosanit Pregl; 2009 Sep; 66(9):738-43. PubMed ID: 19877554
[TBL] [Abstract][Full Text] [Related]
40. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]